Main Line Health System and Affiliates (MLH)

Executive Vice President and CFO Leigh Ehrlich oversees treasury and investment operations under CEO Ed Jimenez. The investment committee includes board members and external professionals such as Joseph McLaughlin Jr., a former Chapter Chair of YPO Gold Philadelphia. Day-to-day allocation decisions on venture investments run through the Lankenau Ventures partnership with L2C Partners, which maintains its own deal-review process tied to clinical IP. The Board of Governors, chaired by Elizabeth Balderston, holds ultimate fiduciary authority.

Main Line Health does not report a discrete endowment or pension fund with a public AUM. Its deployable capital sits across three legs: hospital operating reserves, foundation assets held by separate 501(c)(3) entities including Bryn Mawr Hospital Foundation and Lankenau Medical Center Foundation, and direct real estate equity. The system's pension obligations are funded from the consolidated balance sheet but not broken out publicly. No uniform investable-pool figure exists in public filings.

Lankenau Ventures is a partnership between Main Line Health and L2C Partners, a commercialization firm, designed to turn clinical IP developed within the health system into funded startup companies. The structure functions as a captive venture studio where Main Line Health contributes intellectual property and clinical validation expertise while L2C Partners provides deal structuring and external fundraising support. Investments span health-tech, medical devices, and digital-health tools emerging from the system's research activity, particularly at Lankenau Medical Center and through the CHOP clinical affiliation.

MLH does not publicly disclose any fund-of-funds or separately managed account relationships for its operating or pension assets. The only externally-facing investment program with public visibility is the Lankenau Ventures growth-capital vehicle, which operates alongside the system's direct real estate portfolio. No public equity or fixed-income allocation is documented in open sources, though pension obligations almost certainly carry liquid-market exposure that the system does not detail.

The system directly holds medical office assets including Ellis Preserve Buildings 3803 and 3809 in Newtown Square, Southpoint 2 and 3 in Berwyn, and Main Line Health Radnor at 240 N Radnor Chester Road. The St. Charles Borromeo Seminary site in Wynnewood, acquired for system expansion, is a mixed-use redevelopment opportunity. Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital, Riddle Hospital, and Bryn Mawr Rehabilitation Hospital constitute the core operating real estate, each held on the system's balance sheet (public record).

No direct co-investment activity with outside general partners is documented publicly. The Lankenau Ventures structure is the closest analogue — it pairs a commercialization partner with the health system's clinical assets but does not invest in third-party funds. The system has not published any co-investment policy or disclosed co-investment activity alongside Philadelphia-area healthcare investors or university venture arms.

The CHOP affiliation brings pediatric subspecialty research and clinical trial infrastructure into Main Line Health's network, expanding the set of IP that could feed Lankenau Ventures. The relationship is clinically governed through shared protocols and physician credentialing rather than a formal investment partnership. No joint investment vehicle between MLH and CHOP exists in the public record, but the affiliation likely generates deal flow for commercialization efforts touching pediatric health-tech.